landec corporation (nasdaq:lndc) is a leading innovator of diversified health and wellness solutions within the packaged food and biomaterial markets. apio, landec's food business, is the leader in branded, packaged fresh vegetables in north america, utilizing its proprietary breatheway® packaging technology to naturally extend the shelf life of fresh produce. apio combines this technology with the capabilities of a large national fresh produce supplier to offer healthy fresh vegetable products under the eat smart® brand to consumers through club and retail grocery stores. lifecore biomedical, landec's biomaterial business, is a fully integrated contract development and manufacturing organization (cdmo) that offers expertise and capabilities in fermentation, specialty formulation, aseptic filling and final packaging for fda regulated medical devices and drugs to customers for applications in a wide array of markets including ophthalmic, orthopedic and oncology. for more information abo
Company profile
Ticker
LFCR
Exchange
Website
CEO
Albert Bolles
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LANDEC CORP \CA\
SEC CIK
Corporate docs
Subsidiaries
Curation Foods, Inc. • Lifecore Biomedical Operating Company, Inc. ...
IRS number
943025618
LFCR stock data
Latest filings (excl ownership)
8-K
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
19 Apr 24
NT 10-Q
Notice of late quarterly filing
8 Apr 24
8-K
Results of Operations and Financial Condition
1 Apr 24
8-K
Changes in Registrant's Certifying Accountant
26 Mar 24
8-K
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes
20 Mar 24
8-K
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023
20 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal
16 Feb 24
8-K
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
12 Jan 24
NT 10-Q
Notice of late quarterly filing
10 Jan 24
Transcripts
LFCR
Earnings call transcript
2023 Q4
31 Aug 23
LFCR
Earnings call transcript
2023 Q3
1 Jun 23
LFCR
Earnings call transcript
2023 Q1
6 Oct 22
LFCR
Earnings call transcript
2022 Q4
11 Aug 22
LFCR
Earnings call transcript
2022 Q3
6 Apr 22
LFCR
Earnings call transcript
2022 Q2
6 Jan 22
LFCR
Earnings call transcript
2021 Q4
29 Jul 21
LFCR
Earnings call transcript
2021 Q3
8 Apr 21
LFCR
Earnings call transcript
2021 Q2
6 Jan 21
LFCR
Earnings call transcript
2021 Q1
7 Oct 20
Latest ownership filings
SC 13D/A
22NW Fund, LP
29 Feb 24
SC 13G/A
DIMENSIONAL FUND ADVISORS LP
9 Feb 24
4
Joshua Schechter
2 Feb 24
4
Nathaniel Calloway
2 Feb 24
4
NELSON OBUS
2 Feb 24
4
JEFFREY L EDWARDS
2 Feb 24
4
Raymond H Diradoorian
2 Feb 24
4
LOVAS KATRINA HOUDE
2 Feb 24
4
Craig A. Barbarosh
2 Feb 24
4
John D Morberg
22 Jan 24
Financial summary
Quarter (USD) | Feb 23 | Nov 22 | Aug 22 | May 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | May 22 | May 21 | May 20 | May 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.95 mm | 2.95 mm | 2.95 mm | 2.95 mm | 2.95 mm | 2.95 mm |
Cash burn (monthly) | 1.29 mm | (no burn) | 5.13 mm | 7.64 mm | 4.23 mm | 1.63 mm |
Cash used (since last report) | 18.03 mm | n/a | 71.51 mm | 106.49 mm | 58.95 mm | 22.68 mm |
Cash remaining | -15.08 mm | n/a | -68.56 mm | -103.54 mm | -56.00 mm | -19.73 mm |
Runway (months of cash) | -11.7 | n/a | -13.4 | -13.6 | -13.2 | -12.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 73 |
Opened positions | 6 |
Closed positions | 15 |
Increased positions | 17 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 131.77 bn |
Total shares | 30.91 mm |
Total puts | 221.50 k |
Total calls | 99.32 k |
Total put/call ratio | 2.2 |
Largest owners | Shares | Value |
---|---|---|
Wynnefield Capital | 4.92 mm | $37.15 bn |
Wynnefield Partners Small Cap Value | 3.95 mm | $25.06 mm |
Wynnefield Partners Small Cap Value LP I | 3.58 mm | $22.72 mm |
22NW Fund | 3.17 mm | $26.47 mm |
Legion Partners Asset Management | 2.94 mm | $22.18 bn |
Greenhaven Road Investment Management | 2.19 mm | $165.49 mm |
22NW | 1.76 mm | $13.25 bn |
Vanguard | 1.35 mm | $10.19 bn |
Cove Street Capital | 1.11 mm | $7.47 bn |
MS Morgan Stanley | 794.94 k | $6.00 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Feb 24 | Nathaniel Calloway | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,981 | 0.00 | 28,069 |
1 Feb 24 | Nathaniel Calloway | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,981 | 0.00 | 0 |
1 Feb 24 | Nelson Obus | Common Stock | Option exercise | Acquire M | No | No | 0 | 9,554 | 0.00 | 88,687 |
1 Feb 24 | Nelson Obus | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 9,554 | 0.00 | 0 |
1 Feb 24 | Edwards Jeffrey L | Common Stock | Option exercise | Acquire M | No | No | 0 | 9,554 | 0.00 | 49,667 |
1 Feb 24 | Edwards Jeffrey L | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 9,554 | 0.00 | 0 |
1 Feb 24 | Raymond H Diradoorian | Common Stock | Option exercise | Acquire M | No | No | 0 | 9,554 | 0.00 | 39,978 |
1 Feb 24 | Raymond H Diradoorian | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 9,554 | 0.00 | 0 |
1 Feb 24 | Houde Lovas Katrina | Common Stock | Option exercise | Acquire M | No | No | 0 | 9,554 | 0.00 | 59,906 |
1 Feb 24 | Houde Lovas Katrina | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 9,554 | 0.00 | 0 |
News
Lifecore Biomedical, Inc. Receives Notice From Nasdaq Regarding Delayed Quarterly Report For The Fiscal Quarter Ended February 25, 2024 And Its Continued Delay In Filing Its Quarterly Report On Form 10-Q For The Quarterly Periods Ended August 27, 2023 And November 29, 2023
19 Apr 24
Dow Surges 350 Points; Fed Holds Rates Steady
20 Mar 24
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
20 Mar 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
20 Mar 24
Crude Oil Dips 2%; Signet Jewelers Shares Spike Higher
20 Mar 24
Press releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. - LFCR
20 Apr 24
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation – LFCR, LNDC
20 Apr 24
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDC
19 Apr 24
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report
19 Apr 24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. – LFCR
16 Apr 24